Immuno-oncology

#Drug development #Drug discovery #Immuno-oncology #Immunomodulators #Immunotherapy #Oncology

Podcast: Keep up to date with DDW Highlights

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  DDW’s Diana Spencer has selected five stand-out news headlines this week, which all relate to immunotherapy… Read More

#News

#Drug development #Drug discovery #Immuno-oncology #Immunomodulators #Immunotherapy #Oncology

This week in drug discovery (1-5 May)

News round-up for 1-5 May by DDW Digital Content Editor Diana Spencer. My five stand-out news headlines this week all relate to immunotherapy or immunomodulatory therapies for cancer, particularly advances in our understanding of how other factors in the body, i.e., vitamin D levels and the… Read More

#News

Induced Pluripotent Stem Cells (iPSCs)
#Acquisition #allogeneic cell therapies #Cancer research #Eterna Therapeutics #Exacis Biotherapeutics #Immuno-oncology #iPSC

Eterna acquires Exacis’ allogeneic immuno-oncology platform

Eterna Therapeutics, a life science company focused on mRNA cell engineering, has acquired Exacis Biotherapeutics’ immuno-oncology platform. The acquisition will provide Eterna with a pipeline of allogeneic immuno-oncology products under development for the treatment of haematologic and solid tumours. The deal also provides Eterna… Read More

#Business & Investment #News

#Antibodies #Cancer research #Cancer vaccine #DDW Highlights podcast #Drug discovery #Immuno-oncology #Immunotherapy #Oncology

New episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As March draws to a close, this week’s key announcements have demonstrated the breadth of… Read More

#News

#Antibodies #Cancer research #Cancer vaccine #Drug discovery #Immuno-oncology #Immunotherapy #Oncology

This week in drug discovery (27-31 March)

News round-up for 27-31 March by DDW Digital Content Editor Diana Spencer.   As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and antibody-based treatments all currently under investigation around the world.  The… Read More

#News

Modern medical science laboratory
#Astellas Pharma #Cancer research #Collaboration #Computer modelling #Immuno-oncology #MIMETAS #Oncology #Partnership

Improving immuno-oncology therapies using tumour modelling

Astellas Pharma and MIMETAS, which specialises in human disease modelling, have entered a strategic partnership to develop treatments for cancer. The companies will use MIMETAS’ tumour models to support the next generation of immuno-oncological therapies. “We are excited to make this next step in… Read More

#Cancer Research #News

Macrophages
#Antibodies #Cancer research #Collaboration #Immuno-oncology #Japan #Macrophages #Oncology #Partnership #UK

Drug discovery partners from UK and Japan target macrophages

Macomics and Ono Pharmaceutical have entered a worldwide drug discovery collaboration agreement to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer. Under the terms of the agreement, Macomics will identify and characterise antibody candidates against the novel target of interest… Read More

#Cancer Research #News

Colorectal Cancer Awareness Month
#Cancer research #circular RNAs #Colorectal cancer #Immuno-oncology #Immunotherapy #Oncology

Colorectal Cancer Awareness Month: Drug discovery innovation

Diana Spencer explores the different ways the drug discovery sector is tackling colorectal cancer. Colorectal cancer is preventable with screening and often treatable when caught early, yet due to late diagnosis and chemotherapy resistance, it remains the second deadliest cancer in the United States. Read More

#Cancer Research #Exclusive Content

#Assay development optimisation & technology #Cancer immunotherapy #Cancer research #Immuno-oncology #Immunotherapy #Oncology

The evolution of assays for immuno-oncology research

Listen to this article on the DDW Podcast: By Dr Shailendra Singh, founder and CEO of Cellomatics Biosciences. Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. The number of new cases recorded between 2016 and 2018 was… Read More

#Cancer Research #Exclusive Content

Endometrial biopsy
#Cancer research #FDA #GSK #Immuno-oncology #Oncology #Phase I trial #Regulatory

Full FDA approval for endometrial cancer treatment

The US Food and Drug Administration (FDA) has granted full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a US FDA-approved test.  The approval is for endometrial cancer that has progressed on or… Read More

#News #Regulatory

#Breast cancer #Cancer research #CAR-T #Drug development #Drug discovery #Immuno-oncology #Lung cancer #Oncology #World Cancer Day

The DDW Highlights Podcast: World Cancer Day 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As 4 February was World Cancer Day, this week’s update focused on… Read More

#News

#Breast cancer #Cancer research #CAR-T #Drug development #Drug discovery #Immuno-oncology #Lung cancer #Oncology #World Cancer Day

This week in drug discovery (30 January – 3 February)

News round-up for 30 January – 3 February by DDW Digital Content Editor Diana Spencer.  As February 4 is World Cancer Day, this week’s update focuses on developments in the field of oncology. Drugs for lung cancer, lymphoma and breast cancer have received regulatory approvals, an investment boost will … Read More

#News

Growing bacteria to create CAR therapy
#Cancer research #CAR-T #Immuno-oncology #Immunotherapy #Kite Pharma #National Institute for Health and Care Excellence (NICE) #NHS England #Oncology #UK

Ground-breaking CAR-T therapy approved in UK

Hundreds of people with an aggressive form of lymphoma are set to benefit from the first personalised immunotherapy treatment to be recommended for routine use in the NHS.  Axicabtagene ciloleucel (Yescarta, Kite) is a CAR-T therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)… Read More

#News #Regulatory #Trending News

T cells attack a cancer cell
#Financing #Grey Wolf Therapeutics #Immuno-oncology #Investment #Oncology #T cell activation

$49 million raised to fund original immuno-oncology approach

Grey Wolf Therapeutics has closed an oversubscribed $49 million Series B financing co-led by Pfizer Ventures and Earlybird Venture Capital, with investment from Oxford Science Enterprises, British Patient Capital, Canaan and Andera Partners.   Proceeds will support the continued development of the company’s first-of-its-kind immuno-oncology approaches designed to… Read More

#Business & Investment #News #Start-up Zone